Smith & Nephew (LON:SN) Downgraded to “Sector perform” Rating by Royal Bank Of Canada

Royal Bank Of Canada downgraded shares of Smith & Nephew (LON:SN) to a sector perform rating in a research report report published on Thursday,Digital Look reports. They currently have GBX 1,350 price target on the stock.

A number of other research analysts have also recently weighed in on SN. Berenberg Bank reaffirmed a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a research report on Friday, May 1st. UBS Group reaffirmed a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Smith & Nephew has a consensus rating of “Hold” and a consensus target price of GBX 1,185.86.

Smith & Nephew Stock Performance

Shares of SN stock opened at GBX 1,114 on Thursday. The firm has a market cap of £12.21 billion, a price-to-earnings ratio of 40.11, a P/E/G ratio of 0.46 and a beta of 0.74. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The business has a 50 day moving average of GBX 1,231.74 and a 200 day moving average of GBX 1,256.63.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.